Markets

Eye candy: Medical food maker Guardion Health Sciences prepares $7.5 million IPO

Guardion Health Sciences, which sells medical food and devices for retinal diseases, filed new terms for its upcoming IPO on Monday. The deal is expected to price in March.

The San Diego, CA-based company now plans to raise $7.5 million by offering 1.875 million shares at a price of $4 per share, where it would command a market cap of $90 million. The company previously filed in January to raise $8.7 million by offering 2.2 million shares at the same price, after filing its original terms just two days earlier (2.5mm share offering at a range of $3 to $4).

In its latest filing, Guardion Health Sciences also disclosed financial results for the 12 months ended December 31, 2018, and added joint bookrunner WestPark Capital and co-manager Univest Securities. WallachBeth Capital is still serving as lead left.

Guardion Health Sciences was founded in 2009 and booked $1 million in sales for the 12 months ended September 30, 2018. It plans to list on the NYSE under the symbol GHSI.

The article Eye candy: Medical food maker Guardion Health Sciences prepares $7.5 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More